Immune-related Adverse Events — CAR T-Cell Therapy
Publication Date: October 31, 2021
Key Points
Key Points
- Immunotherapy has revolutionized the treatment of many different types of cancers.
- Chimeric antigen receptor T-cell (CAR T) therapy, an expanding immunotherapeutic approach, modifies T cells to redirect them to eradicate malignant cells.
- CAR T-cell therapy is regarded as a “living drug” since cells are expected to persist long term with efficacy that may last for decades.
- CAR T-cell therapy is administered with a single infusion and close monitoring.
- CAR T-cell therapy is associated with severe, even fatal, toxicities such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
- The incidence of CRS has been reported to range from 57%–93%, and ICANS from 20%–70%, based on the agent used.
Key Recommendations
...ey Recommendatio...
...are general recommendations that should be f...
...nded that clinicians manage toxicities as follow...
Management
...agement...
...ecommendations In patients with active i...
...e Release Syndrome RecommendationsH...
...ANS RecommendationsHaving trouble viewin...
...phagocytic Lymphohistiocytosis (HL...
...penias RecommendationsHaving trouble...
Table 5. B-cell Aplasia Recommendati...
...able 6. Disseminated Intravascular Coagulation...
...7. InfectionsHaving trouble viewing t...
...ell TherapiesHaving trouble viewing table? Ex...